TY - GEN
T1 - Suppression of experimental autoimmune myasthenia gravis by intravenous immunoglobulin and isolation of a disease-specific IgG fraction
AU - Fuchs, Sara
AU - Feferman, Tali
AU - Zhu, Kai Yun
AU - Meidler, Roberto
AU - Margalit, Raanan
AU - Wang, Ningshan
AU - Laub, Orgad
AU - Souroujon, Miriam C.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2007/9
Y1 - 2007/9
N2 - Intravenous immunoglobulin (IVIG) administration has been beneficially used for the treatment of a variety of autoimmune diseases including myasthenia gravis (MG). We have demonstrated that IVIG administration in experimental autoimmune MG (EAMG) results in suppression of disease that is accompanied by decreased Th1 cell and B cell proliferation. Chromatography of pooled human immunoglobulins (IVIGs) on immobilized IgG, isolated from rats with EAMG, results in a complete depletion of the suppressive activity of the IVIG. Moreover, the eluate from this EAMG-specific antibody column retains the immunosuppressive activity of IVIG. This study supports the notion that the therapeutic effect of IVIGs is mediated by an antigen-specific anti-immunoglobulin (anti-idiotypic) activity that is essential for its suppressive activity.
AB - Intravenous immunoglobulin (IVIG) administration has been beneficially used for the treatment of a variety of autoimmune diseases including myasthenia gravis (MG). We have demonstrated that IVIG administration in experimental autoimmune MG (EAMG) results in suppression of disease that is accompanied by decreased Th1 cell and B cell proliferation. Chromatography of pooled human immunoglobulins (IVIGs) on immobilized IgG, isolated from rats with EAMG, results in a complete depletion of the suppressive activity of the IVIG. Moreover, the eluate from this EAMG-specific antibody column retains the immunosuppressive activity of IVIG. This study supports the notion that the therapeutic effect of IVIGs is mediated by an antigen-specific anti-immunoglobulin (anti-idiotypic) activity that is essential for its suppressive activity.
KW - Experimental autoimmune myasthenia gravis (EAMG)
KW - Immunotherapy
KW - Intravenous immunoglobulin (IVIG)
KW - Myasthenia gravis (MG)
UR - http://www.scopus.com/inward/record.url?scp=35748958738&partnerID=8YFLogxK
U2 - 10.1196/annals.1423.059
DO - 10.1196/annals.1423.059
M3 - ???researchoutput.researchoutputtypes.contributiontobookanthology.conference???
C2 - 17911471
AN - SCOPUS:35748958738
SN - 1573317098
SN - 9781573317092
T3 - Annals of the New York Academy of Sciences
SP - 550
EP - 558
BT - Autoimmunity, Part B Novel Applications of Basic Research
PB - Blackwell Publishing Inc.
ER -